Future to develop more assays for Bayer:
This article was originally published in Clinica
Executive Summary
Future Diagnostics has won a contract from Bayer Healthcare's diagnostics division to develop a suite of immunoassays for use on the German multinational's line of Advia Centaur analyser systems. In the first phase of the agreement, Future Diagnostics, of Wijchen, the Netherlands, will develop four immunoassays: two fertility tests - one for sex hormone-binding globulin (SHBG) and another for dehydroepiandrosterone sulfate (DHEA); an unconjugated estriol (uE3) test to monitor foetal maturity and well-being; and an assay that detects the D-dimer marker linked to deep vein thrombosis or pulmonary embolism. Future Diagnostics had a previous agreement with Bayer in 2001, when it developed an intact parathyroid (PTH) assay for diagnosis of metabolic bone disease.